Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma.
Hanwool JeonJoonho ByunHayeong KangKyunggon KimEunyeup LeeJeong Hoon KimChang Ki HongSang Woo SongYoung-Hoon KimSangjoon ChongJae Hyun KimSoo Jeong NamJi Eun ParkSeungioo LeePublished in: Journal of translational medicine (2023)
The candidate biomarkers identified in our protein analysis may be useful for predicting the clinical response to anti-angiogenic agents in patients with recurred GBM.